With new Omi­cron da­ta, Ada­gio halts tri­als for vaunt­ed Covid an­ti­body but sees a path ahead

Last month, Ada­gio shares tanked af­ter re­port­ing its Covid-19 an­ti­body saw a 300-fold re­duc­tion in its abil­i­ty to neu­tral­ize the Omi­cron vari­ant. But late Wednes­day, the biotech changed its tune.

The Till­man Gern­gross out­fit said in a press re­lease the an­ti­body is as sim­i­lar­ly po­tent against Omi­cron as the Vir/Glax­o­SmithK­line and As­traZeneca treat­ments, point­ing to three in vit­ro stud­ies con­duct­ed at in­de­pen­dent labs. Of the four mon­o­clon­al an­ti­body cock­tails au­tho­rized by the FDA, on­ly the Vir/GSK and As­traZeneca an­ti­bod­ies have re­tained any ef­fec­tive­ness against Omi­cron.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER